BACKGROUND: Most
type 2 diabetes mellitus patients are obese and have
obesity related vascular
complications .
Exenatide treatment is well known for both decreasing
glycated hemoglobin levels and reduction in
body weight . So, this study aimed to determine the effects of
exenatide on
body composition ,
glycated hemoglobin levels, and
vascular stiffness in obese
type 2 diabetes mellitus patients .
METHODS: For 1 month, 32 obese
type 2 diabetes mellitus patients were administered 5 µg of
exenatide twice daily. The
dosage was then increased to 10 µg.
Patients '
height, body weight,
glycated hemoglobin levels,
lipid profile,
pulse wave velocity (PWV),
body mass index , fat mass, and
muscle mass were measured by using Inbody at baseline and after 3 months of
treatment .
RESULTS: After 3 months of
treatment ,
glycated hemoglobin levels decreased significantly (P=0.007).
Triglyceride , total
cholesterol , and
low density lipoprotein levels decreased, while
aspartate aminotransferase and
alanine aminotransferase levels were no change.
Body weight , and fat mass decreased significantly (P=0.002 and P=0.001, respectively), while interestingly,
muscle mass did not decrease (P=0.289). In addition to,
Waist-to-hip ratio and aortic PWV decreased significantly (P=0.006 and P=0.001, respectively).
CONCLUSION: Effects of short term
exenatide use in obese
type 2 diabetes mellitus with cardiometabolic high
risk patients not only reduced
body weight without
muscle mass loss,
body fat mass, and
glycated hemoglobin levels but also improved aortic PWV in accordance with
waist to hip ratio .